BG
ESPR

Bollard Group’s Esperion Therapeutics ESPR Stock Holding History

Bollard Group’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,121
Closed -$5K – 327
2022
Q1 		$5K Hold
1,121
– – ﹤0.01% 418
2021
Q4 		$6K Hold
1,121
– – ﹤0.01% 421
2021
Q3 		$14K Hold
1,121
– – ﹤0.01% 401
2021
Q2 		$24K Hold
1,121
– – ﹤0.01% 389
2021
Q1 		$31K Hold
1,121
– – ﹤0.01% 374
2020
Q4 		$29K Hold
1,121
– – ﹤0.01% 376
2020
Q3 		$42K Hold
1,121
– – ﹤0.01% 334
2020
Q2 		$58K Buy
+1,121
New +$46.9K ﹤0.01% 326

Other funds holding ESPR

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Bollard Group's ESPR Position: Q2 2022 in Review

Bollard Group sold out of Esperion Therapeutics (ESPR) in Q2 2022, closing a stake of 1,121 shares — an estimated $5K sold.

Bollard Group first reported a position in ESPR in Q2 2020 and held it in 8 quarters. The position peaked at $58K in Q2 2020. 136 funds tracked by Wall St. Rank hold ESPR as of Q2 2022.

  • Bollard Group reported no remaining Esperion Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Bollard Group sold 1,121 Esperion Therapeutics shares in Q2 2022, an estimated $5K.
  • Bollard Group first reported a position in Esperion Therapeutics in Q2 2020 and held it in 8 quarters.
  • Bollard Group's Esperion Therapeutics position peaked at $58K in Q2 2020.
  • 136 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2022.

Based on Bollard Group's 13F filing for Q2 2022, filed 12 Aug 2022.